Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols
Table 3
Risk factors for overall survival and progression-free survival.
Variables
Overall survival
Progression-free survival
Crude HRs (95% CI)
P value
Adjusted HRs (95% CI)
P value
Crude HRs (95% CI)
P value
Adjusted HRs (95% CI)
P value
All ()
Age
<60
1
1
1
1
≥60
1.11 (0.66–1.85)
0.696
0.78 (0.44–1.40)
0.411
1.11 (0.69–1.76)
0.672
0.86 (0.50–1.45)
0.564
T stage
0, 1, 2
1
1
1
1
3, 4
1.51 (0.65–3.51)
0.343
1.39 (0.56–3.43)
0.477
1.90 (0.90–3.99)
0.091
1.65 (0.74–3.67)
0.222
Tumor location
Upper
1
1
1
1
Middle
0.84 (0.39–1.82)
0.658
0.68 (0.31–1.52)
0.352
0.95 (0.46–1.95)
0.877
0.80 (0.38–1.71)
0.560
Lower
0.83 (0.39–1.77)
0.620
0.79 (0.36–1.73)
0.550
1.07 (0.53–2.17)
0.855
0.99 (0.48–2.06)
0.980
Op. complication
No
1
1
1
1
Yes
1.92 (1.14–3.23)
0.014
1.90 (1.09–3.32)
0.024
1.65 (1.04–2.63)
0.034
1.61 (0.98–2.65)
0.066
CCRT response
pCR
1
1
1
1
MRD
1.25 (0.74–2.10)
0.399
0.97 (0.53–1.78)
0.919
1.31 (0.82–2.09)
0.264
1.07 (0.62–1.84)
0.819
CCRT complication
No
1
1
1
1
Yes
0.76 (0.44–1.33)
0.335
0.80 (0.45–1.42)
0.444
0.88 (0.54–1.44)
0.610
0.97 (0.58–1.62)
0.905
CCRT regimen
Taxane-incorporated CCRT
1
1
1
1
PF
1.97 (1.16–3.35)
0.013
2.00 (1.13–3.55)
0.017
1.51 (0.94–2.42)
0.086
1.52 (0.91–2.53)
0.112
Post-CCRT pathologic T staging. pCR: pathologic complete response; MRD: microscopic residual disease. Taxane-incorporated CCRT: modified TPFL or TP-HDFL and then neoadjuvant CCRT (TP regimen), or the standard neoadjuvant CCRT with TP regimen.
